InvestWiser

Active Biotech AB

ACTINasdaq StockholmHealthcareMarket value 92 m SEK
3.48SEK −0.7%
last day · Price as of 18 November 2026

The answer first

Does Active Biotech beat the market?

No, Active Biotech has not beaten the market over the last year.

Active Biotech−43.1%Stockholm (OMXSGI)+18.4%
  • The ranking · Quality, value and trend combined

    Better than 8% of Nordic stocks

    • Quality67
    • Value3
    • Trend6

    No. 169 of 195 in healthcare

Max for seven days

Follow Active Biotech with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Active Biotech

From today, at a price of 3.48 SEK. Write why you follow Active Biotech, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Active Biotech

Your first answer is free, no account needed.

Do you own Active Biotech, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Active Biotech and a few more. Free, no card.

Past year against the exchange and Super Stock
Active Biotech−43.1%Stockholm (OMXSGI)+18.4%Super Stock+45.9%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Active Biotech has fallen 43.1% over the past year, including dividends.
  • Overall, Active Biotech ranks better than 8% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 92.1%. The price is 100.0% below its peak now.

What do analysts think of Active Biotech?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

8

Quality, value and trend together. Better than 8% of Nordic stocks.

No. 169 of 195 in healthcare

Quality67
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 93 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.06
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−124.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value3
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 176 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.1
  • P/SPrice divided by sales954.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend6
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 171 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−34.4%
  • 6 months−51.3%
  • 9 months−9.7%
  • 12 months−43.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+8.9%
3 years, per year
−46.4%
5 years, per year
−39.2%
10 years, per year
−33.3%
Largest fall, 3 years
−92.1%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
107.9%
How much the price swings over a year
Beta, 1 year
1.81
How much the price moves when the market moves

Return with dividends reinvested.

About Active Biotech

Active Biotech AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 5 employees.

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors.

See the full analysis of Active Biotech.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market